Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Margaret Thomas, MPH
CONTACT
Katia Khouri, MD
CONTACT
Lead
University of Alabama at Birmingham
The study is a phase II, single arm study in which all patients will receive the study drug. Participants will include older/frail patients with metastatic breast cancer. All patients will be treated with capecitabine 1000 mg daily. There will be a total of 40 participants with measurable disease on this trial. The study will encompass participants with locally advanced unresectable/metastatic breast cancer with measurable disease, who progressed on at least 1 prior therapy in the metastatic setting. Breast cancer subtypes include HR+ HER2 negative, or TNBC, age ≥ 60 years old, or frail patients at a younger age. ECOG PS 0- 2. The study will discontinue if progressive disease or unacceptable toxicity is noted.
Age
60–any
Sex
FEMALE
Healthy volunteers
Not accepted